SCHEMBL15701141

SCHEMBL15701141

O=C(Nc1ccc2nc(NC(=O)C3(c4ccc(Cl)c(Cl)c4)CC3)sc2c1)c1cscn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.44
BRAF P15056 1/20 0.44
HPGD P15428 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RAB9A P51151 4/20 0.41
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
CSNK1D P48730 3/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 2/20 0.40
HDAC1 Q13547 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15701098 0.89 RAB9A (0.45) HPGDMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL15701140 0.85 RAB9A (0.44) HPGDMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL15701267 0.84 CSNK1D (0.45) HPGDMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL15701153 0.83 CSNK1D (0.61) RAF1BRAFHPGDKMT2ASMN1; SMN2
SCHEMBL15701034 0.81 CSNK1D (0.44) HPGDMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL17148310 0.81 CSNK1D (0.44) HPGDMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL15701022 0.78 RAF1 (0.47) RAF1BRAFHPGDMEN1KMT2A
SCHEMBL15701138 0.75 WNT3A (0.58) HPGDMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL15701151 0.74 CSNK1D (0.57) HPGDMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL15701155 0.74 MEN1 (0.59) MEN1KMT2ASMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2914592-B1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INT (DE) 2017-10-11 EP disclosed
US-9334249-B2 Inhibitors of cytomegalovirus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 US disclosed
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-08 US disclosed
WO-2014070979-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS CDKN1A, CCNA1, IFNAR1 RAF1 2629/4885BRAF 3747/4885HPGD 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.